ARIAD Pharmaceuticals SUCCEED trial of oral ridaforolimus on the right track ARIAD Pharmaceuticals.

For the nine-month period finished September 30, 2009, ARIAD reported a net loss of $62.0 million, or $0.70 per share, in comparison to a net lack of $54.3 million, or $0.78 per share for the nine-month period ended September 30, 2008. These raises and noncash charges were offset in huge part by decreases generally and administrative expenses in 2009 2009 in comparison to 2008, due to reduction in costs and activities related to corporate and commercial development initiatives and patent litigation. On August 7, 2009, ARIAD raised net proceeds of $35.6 million in an underwritten offering of 21.85 million shares of its common stock.Kaiser Health News, an editorially independent information service, is an application of the Kaiser Family members Foundation, a nonpartisan healthcare policy research corporation unaffiliated with Kaiser Permanente.

3 questions identify children vulnerable to passive smoking Pediatricians may reliably identify children in risk for environmental tobacco smoke exposure by asking parents just 3 questions, according to an article in the May problem of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals. Contact with tobacco smoke cigarettes impairs children’s respiratory wellness, putting them at elevated threat of pneumonia, bronchiolitis, asthma and ear infections with greater prices of hospitalization and longer recovery intervals from these circumstances than unexposed children, according to background details in this article.